Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health reported Fourth Quarter 2025 revenue of $642.3 million, roughly flat year-over-year, and a net loss of $25.1 million, or $0.14 per share. Adjusted EBITDA rose 12% to $83.8 million as Integrated Care offset softer BetterHelp performance.
For Full Year 2025, revenue declined 2% to $2.53 billion while net loss narrowed sharply to $200.3 million from $1.00 billion, helped by much lower goodwill impairments. Adjusted EBITDA fell 10% to $281.1 million. Operating cash flow was $294.4 million and free cash flow was $166.9 million. Guidance for 2026 calls for revenue of $2.47–$2.59 billion, adjusted EBITDA of $266–$308 million, and free cash flow of $130–$170 million, with Integrated Care growing modestly and BetterHelp expected to decline or remain roughly flat.
Smith Michael S reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Michael S. Smith received a grant of 53,648 restricted stock units, each representing the right to receive one share of TDOC common stock. One-third of these units vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. filed an initial insider ownership report for board member Michael S. Smith. This Form 3 filing establishes him as a reporting person under insider trading rules and provides the baseline disclosure of his existing relationship to the company as a director.
Teladoc Health expanded its board of directors and appointed Michael Smith as a new independent director, effective February 18, 2026. He was also named to the audit committee and the nominating and corporate governance committee, and is designated an “audit committee financial expert” under SEC and NYSE rules.
Smith brings more than three decades of experience in insurance and financial services, including senior roles at Voya Financial and Lincoln Financial, and currently serves as Executive Chairman of Talcott Financial Group. Teladoc Health also announced it will release fourth quarter 2025 results on February 25, 2026, followed by a conference call at 5:00 p.m. ET.
Teladoc Health, Inc. reported that long-serving director Thomas G. McKinley notified the company on February 8, 2026 of his intention to retire from the Board, effective February 20, 2026. The company states that Mr. McKinley is retiring for personal reasons and not due to any disagreement with the company on any matter.
Teladoc Health’s Chief Accounting Officer reported routine equity transactions in company stock. On 01/02/2026, restricted stock units converted into 2,083 shares of Teladoc Health common stock on a one-for-one basis. On 01/05/2026, the officer sold 758 shares at $7.145 per share to cover tax withholding obligations related to the vesting of restricted stock units.
After these transactions, the officer held 6,686 shares of Teladoc Health common stock directly and 14,584 restricted stock units. The filing notes that an earlier grant of 25,000 restricted stock units from October 1, 2024 vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health director reports RSU conversion into common stock. On 12/19/2025, the reporting person converted 1,016 restricted stock units into an equal number of Teladoc Health common shares, increasing directly held common stock to 9,145 shares. A related derivative line shows 1,016 restricted stock units being settled for 1,016 common shares at an exercise price of $0, leaving 3,050 restricted stock units beneficially owned.
The filing notes that these restricted stock units were originally granted on September 20, 2023, in an award of 12,195 units that vest one‑third on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. disclosed that board member J. Eric Evans plans to retire from its Board of Directors. He informed the company on December 11, 2025 that he will not stand for reelection at Teladoc Health’s 2026 Annual Meeting of Stockholders and will retire from the Board at the conclusion of that meeting.
Mr. Evans has served as a director since 2023. The company notes that he is retiring for personal reasons and that his decision is not due to any disagreement with Teladoc Health on any matter.
Teladoc Health, Inc. reported that on December 9, 2025 it amended its 2023 Employment Inducement Incentive Award Plan. The amendment increases the number of shares of common stock reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, bringing the total reserve to 7,280,000 shares of common stock.
This plan is used to grant equity awards to new employees as inducement for joining the company. Teladoc notes that the 2023 Inducement Plan was adopted by the Board without stockholder approval in reliance on NYSE Rule 303A.08, which permits certain inducement awards without a shareholder vote.
Teladoc Health’s chief executive officer reported new stock activity in a Form 4 filing. On December 10, 2025, 39,160 restricted stock units vested and converted into the same number of shares of Teladoc common stock. On December 11, 2025, the CEO sold 17,138 shares of common stock at an average price of $7.6343 per share to cover tax withholding obligations tied to this vesting.
After these transactions, the CEO directly owned 201,036 shares of Teladoc common stock and held 234,963 restricted stock units. The restricted stock units referenced stem from a grant of 469,924 units made on June 10, 2024, which vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments.